(NaturalNews) In an unprecedented change of posture, the New England Journal
of Medicine has reversed itself on the issue of whether Vytorin causes
cancer. In the initial release of data back in July, NEJM stood by Merck and
Schering-Plough, who hired an Oxford consultant to rule that a 50%
statistically significant increased risk of cancer was by chance. I pointed
out in an earlier posting that such statistical manipulation, based
primarily on the opinion of the Oxford reviewer, was ridiculous. NEJM has
had a sudden change of heart and now agrees with me.
On September 2, 2008 NEJM published the full study in question, along with
the Oxford report, and its own editorial now stating "Whether the increased
mortality risk is due solely to the play of chance is uncertain. Ezetimibe
[the Zetia portion of Vytorin] interferes with the gastrointestinal
absorption not only of cholesterol, but also of other molecular entities
[fat soluble antioxidants and isoprenoids] that could conceivably affect the
growth of cancer cells. Physicians and patients are unfortunately left for
now with uncertainty about the efficacy and safety of the drug." This rare
reversal of opinion has sent a shock wave through Big Pharma's world, like
having your stamp of approval withdrawn at the last minute.
Vytorin is the controversial cholesterol lowering drug that is the center of
a major advertising fraud that netted Merck and Schering-Plough over 10
billion dollars in sales in the past two years. Merck and Schering-Plough
are facing congressional investigation, various state attorney general
investigations, and plaintiff class action lawsuits. All the negative
publicity has caused sales to fall off, yet the questionable drug is still a
top seller for Merck and Schering-Plough in 2008.
Cholesterol Disease Mongering Based on Outright Fraud
Underneath the advertising fraud is a far more damaging prospect from the
Big Pharma point of view, that the theory of lowering LDL cholesterol with
drugs to prevent heart disease is itself a major fraud that has been
perpetrated on the American public for the past decade. Indeed, while
Vytorin is the most effective drug combination of all time in terms of
lowering LDL, doing so does not produce cardiovascular health or reduce
cardiovascular mortality.
The current study that uncovered cancer risk, called the SEAS trial, was
supposed to prove that patients whose heart valves were partially blocked
would benefit from Vytorin and not need valve replacement therapy or have
heart failure. In this regard, the SEAS trial showed that Vytorin is
worthless, despite lowering LDL cholesterol. This finding is consistent with
another unrelated study (GISSI-HF trial) just published in The Lancet that
showed fish oil could save lives in patients with heart failure, while the
statin drug Crestor could not. The researchers in this study concluded that
"patients with heart failure should not be treated with statins."
Adding more alarm to the statin industry's safety is another article
published in the NEJM just last week. It reported on a detailed analysis of
the human genome in those with statin-induced muscle damage. Scientists
uncovered an alteration in a gene that causes statin drugs to be more
readily absorbed by the liver, thereby making the drugs very toxic. Fifteen
percent of our population has the risk-related gene variant. At this time no
screening is done to see who is at potential risk, meaning that 1 in 6
patients taking statins are likely to be damaged to a greater or lesser
degree based on this one variable alone. Whatever happened to "first do no
harm?"
Low cholesterol now linked to disease
Adding fuel to the low cholesterol and cancer link was another study
recently published in the Canadian Medical Association Journal that found a
33% increased risk of cancer and mortality in type II diabetic patients when
their LDL cholesterol reached 107 and a 50% increase when their LDL reached
87. This is particularly alarming because type II diabetic patients (like
the late Tim Russert) are aggressively treated with statins to lower their
cholesterol to the very numbers that are now associated with increased
cancer risk and death from any cause.
Pathetically, various forces in the Big Pharma world are recommending that
children as low as 7 months of age have their LDL cholesterol levels
maintained at 50 for their entire lives (which obviously will require statin
drugs since such levels are highly abnormal). Big Pharma is always looking
to expand their market share - focusing now on our children - a truly sad
state of affairs.
Statin drugs do not produce cardiovascular health. The lower your
cholesterol goes, the more likely you are to develop cancer and/or die from
any cause. This is massive public health fraud on a grand scale.
Additional comments by Mike Adams, the Health Ranger
I strongly agree with this timely assessment of the Vytorin cancer risk. As
Richards has rightly pointed out, the original findings linking Vytorin to
cancer appear to have been fraudulent swept under the rug by typical Big
Pharma fraud and misrepresentation.
The NEJM's reversal on this issue is sending shockwaves through the
industry. It's also reminding consumers that you cannot trust the medical
journals because they will willingly participate in pharmaceutical fraud,
and then they'll later reverse themselves when the truth comes out through
other channels. At any given point in time, there is no way to know if a
particular study appearing in a drug-funded medical journal is in the
"fraud" phase or the "reversal" phase. Today's highly-touted "miracle" drug
may become next year's poison.
Can you imagine the outcry by the FDA if it were found that an HERB
increased the risk of cancer by a whopping 50 percent? The FDA would ban the
herb and denounce it as dangerous at any dose. Curiously, when an
FDA-pharmaceutical achieves the same negative distinction, the FDA remains
utterly silent. There is no drug too dangerous for public consumption, it
seems, and there is no clinical trial that cannot be warped and reshaped to
adhere to the evil designs of drug companies.
Folks, if you are currently taking statin drugs, you have been duped. The
disease is fictitious (there is no such thing as "high cholesterol" disease)
and the drugs are deadly. Besides, you can achieve the same cholesterol
balancing effects with red yeast rice, garlic supplements, B vitamins,
blueberries and mineral supplementation. You don't need drugs to have a
healthy cardiovascular system; all you need is some good nutrition and
regular exercise. Come to think of it, Byron Richards' company
(www.WellnessResources.com) manufactures some of the highest-quality
nutritional supplements in the world, and they protect cardiovascular health
phenomenally well.
Resources
Links to NEJM articles:
Change of opinion: http://content.nejm.org/cgi/content/ful...
Full SEAS Vytorin trial: http://content.nejm.org/cgi/content/ful...
Gene damage study: http://content.nejm.org/cgi/content/abs...
Links to Lancet articles on fish oil and Crestor:
http://www.thelancet.com/journals/lance...
http://www.thelancet.com/journals/lance...
Links to Canadian Medical Association Journal article:
http://www.cmaj.ca/cgi/content/full/179...
Link to a fully referenced version of this article:
http://www.wellnessresources.com/conten...
Link to more health articles by this author:
http://www.wellnessresources.com/health...
About the author: Byron J. Richards, Board-Certified Clinical Nutritionist,
nationally-renowned nutrition expert, and founder of Wellness Resources is a
leader in advocating the value of dietary supplements as a vital tool to
maintain health. He is an outspoken critic of government and Big Pharma
efforts to deny access to natural health products and has written
extensively on the life-shortening and health-damaging failures of the
sickness industry. www.wellnessresources.com askbyron@wellnessresources.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment